Expanded eligibility criteria for COVID-19 oral antiviral treatments, Paxlovid^® (nirmatrelvir and ritonavir) and molnupiravir (Lagevrio^®)

Page last updated: 10 July 2022

Updated September 2022

Commencing 11 July 2022, the eligibility criteria for COVID-19 oral antiviral treatments, nirmatrelvir and ritonavir (Paxlovid^®) and molnupiravir (Lagevrio^®), will be expanded.

New eligibility includes updated age limits and risk factors.

Additional information can be found in the Covid 19 Fact sheets.